Generic Name:
crisantaspase recombinant
Project Status:
Active
Therapeutic Area:
Acute lymphoblastic leukemia
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Brand Name:
Rylaze
Project Line:
Reimbursement Review
Project Number:
PC0301-000
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
Rylaze (crisantaspase recombinant) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of: Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Leukemia
Indications:
Rylaze (crisantaspase recombinant) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of: Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.